Advertisement

Topics

AZ ends Calquence trial early after Phase 3 success in chronic lymphocytic leukaemia

05:39 EDT 8 May 2019 | Pharmafile

AstraZeneca has unveiled new Phase 3 data on the efficacy of its Bruton tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) in the treatment of previously-treated patients with chronic lymphocytic leukaemia (CLL), demonstrating that the therapy “significantly increased the time patients live without disease progression” in interim analysis.

In the study, 310 participants were randomised into two groups, with one group receiving Calquence 100mg twice daily, and the second group receiving rituximab plus either Roche’s Mabthera (idelalisib) or Gilead’s Zydelig (bendamustine).

read more

Original Article: AZ ends Calquence trial early after Phase 3 success in chronic lymphocytic leukaemia

NEXT ARTICLE

More From BioPortfolio on "AZ ends Calquence trial early after Phase 3 success in chronic lymphocytic leukaemia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...